Ohio Rep. Michael Rulli Sold Up to $100K Worth of Alphabet Stock

Bloomberg Reported Google, Constellation Energy Near $1B Deal For Nuclear Power

https://www.bloomberg.com/news/articles/2026-10-06/google-constellation-near-billion-dollar-deal-for-nuclear-power

'Wall Street banks launch record $60B chip deal for Broadcom and Anthropic'- Financial Times

Amazon, Alphabet, Tesla Stock Rises: Robinhood Traders Sell Anyway

Amazon, Alphabet and Tesla rose Friday, but Robinhood traders sold all three. The monthly data suggests profit-taking, not an AI trade exit.

Tom Lee vs. AI Debt Trap: What Happens When 10-Year Bonds Fund 2-Year Microchips?

Tom Lee sees lower yields boosting tech and crypto. But rising AI debt raises a bigger question: Can hyperscalers earn enough to justify the spending?

Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock

Eli Lilly, the only healthcare stock in the trillion-dollar club, has rallied 400% over five years driven by its successful GLP-1 drugs Mounjaro and Zepbound. However, with a valuation of 40x trailing earnings and slowing growth prospects, the stock faces significant headwinds from intensifying competition in the GLP-1 market from companies like Pfizer and Viking Therapeutics. The author suggests the stock may have more downside risk than upside potential at current valuations.

Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight

The type 2 diabetes market is projected to experience steady growth through 2036, driven by rising global prevalence, obesity, and adoption of next-generation therapies including GLP-1 receptor agonists and SGLT2 inhibitors. Key emerging drugs from major pharmaceutical companies like Novo Nordisk, Eli Lilly, and Boehringer Ingelheim are expected to reshape the market landscape with improved glycemic control and weight management benefits.